Joe Manganiello battled a cascade of autoimmune-related illnesses for seven years, resulting in a life-saving organ amputation.
Amyloid deposition can begin two to three decades before the onset of clinical cognitive symptoms.
About 25% of community-dwelling people in their seventies have amyloid in their brains without any symptoms of dementia.
By age 90, approximately 44% of community-dwelling people have brain amyloid without dementia symptoms, undermining blood-test specificity.
Gayatri Devi's slow-titration protocol for APOE4 carriers on anti-amyloid monoclonal antibodies yields only a 4% rate of ARIA, far below standard protocols.
Autopsy studies show that between 98% and 99% of Alzheimer's patients have some form of concomitant primary brain pathology, most commonly vascular disease.
About 40% of Alzheimer's patients eventually develop some level of Lewy body pathology, illustrating significant dementia overlap.
Anti-amyloid therapies like lecanemab and donanemab show only 0.3–0.4 point improvements on the 18-point CDR Sum of Boxes scale, a modest but potentially meaningful shift.
Approximately 30% of patients enrolled in Alzheimer's drug trials did not actually have Alzheimer's by pathology, having been misdiagnosed clinically.
Carrying two copies of the APOE4 allele increases Alzheimer's risk by approximately 60% compared to the APOE3/3 wild type, analogous to carrying the BRCA gene for breast cancer.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.